Coya Therapeutics, Inc.

As of August 12, 2025, Coya Therapeutics, Inc. is considered overvalued with a valuation grade of "does not qualify," reflected by a Price to Book Value of 2.94, a negative ROE of -51.35%, and poor stock performance compared to the S&P 500, returning -5.28% against the index's 17.14%.

As of March 19, 2024, Coya Therapeutics, Inc. is rated as "risky" and overvalued due to negative financial metrics, including a P/E ratio of NA, an EV to EBITDA of -3.23, and a ROE of -51.35%, with its current price of $5.79 significantly below its 52-week high of $10.24 and a 1-year return of -4.21% compared to the S&P 500's 10.26%.

As of June 18, 2025, the trend is mildly bearish due to bearish MACD and moving averages, despite some mildly bullish signals from Dow Theory and OBV, indicating moderate bearish sentiment overall.

Coya Therapeutics, Inc. is a micro-cap company in the miscellaneous industry, reporting net sales of $0 million and a net loss of $7 million as of March 2025, with a market cap of $88.88 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -51.35%.

As of Jun 18, Coya Therapeutics, Inc. has a market capitalization of 88.88 million, with net sales of 3.69 million and a net profit of -17.14 million over the last four quarters. The company reported shareholder's funds of 39.58 million and total assets of 44.35 million as of Dec 24.